A study protocol was mentioned in an ongoing exploring phase I/II clinic trial on 30 patients with EGFR mutation–positive stage III/IV NSCLC that will evaluate the efficacy and safety of using allogeneic CD3+CD8+ iNKT cells in combination with EGFR-TKIs such as gefitinib (103). This evidence concerns the gene CD8A and non-small cell lung carcinoma.